Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Sotrovimab Or Xevudy Market Size, Value And Growth Trends Through 2030
Growth during the historic period was driven by several factors: the emergency authorization granted to monoclonal antibodies for COVID-19, the elevated hospitalization risk observed in the early stages of the pandemic, the swift rollout of antibody-based therapies, government purchases of antiviral drugs, and the broadening of infrastructure dedicated to infusion-based treatments.
The expansion observed during the forecast period is driven by the emergence of antibody therapies effective against different viral variants, heightened emphasis on readiness for pandemics to come, larger financial commitments to antiviral biologic treatments, a broader network of outpatient infusion capabilities, and the incorporation of monoclonal antibodies into established care guidelines. Key developments shaping this period include the growing reliance on monoclonal antibody treatments, an intensified concentration on addressing viral infections at early stages, the widening scope of specialized antiviral biologics, a stronger priority on safeguarding vulnerable populations, and accelerated progress in creating therapeutics designed for pandemic responses.
Download A Free Sample Report For Comprehensive Market Insights:
#Sotrovimab Or Xevudy Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing number of COVID-19 cases is anticipated to propel the expansion of the sotrovimab (Xevudy) market in the upcoming period. COVID-19, an illness triggered by the SARS-CoV-2 virus, transmits via respiratory droplets and manifests symptoms ranging from mild fever to severe respiratory complications. Preventive measures like vaccines and proper hygiene help curb its dissemination. An upsurge in COVID-19 infections is attributed to emerging variants, waning immunity, relaxed restrictions, seasonal indoor activities, and inconsistent vaccine coverage. By neutralizing the virus early in high-risk patients, sotrovimab prevents severe outcomes such as hospitalization or death. As an example, a March 2023 report from the Office for National Statistics, the UK’s official statistics authority, indicated that around 1.9 million individuals in the UK (2.9% of the population) had reported COVID. Of these, 92% had contracted the virus more than 12 weeks earlier, with 69% enduring symptoms for over a year and 41% for more than two years. Consequently, the escalating prevalence of COVID cases is set to fuel the growth of the sotrovimab or Xevudy market.
Increased healthcare investments are projected to propel the sotrovimab (Xevudy) market forward in the years ahead. Healthcare investments denote the aggregate spending on medical services, including treatments, medications, and hospital care, within a defined timeframe. This spending is on the rise due to an aging population, heightened healthcare demands, breakthroughs in medical technology, and escalating costs for services and pharmaceuticals. Such investments enhance sotrovimab (Xevudy) by funding research and development, scaling up production, and improving access for high-risk patients via collaborations and distribution channels. For instance, a May 2024 report from the Office for National Statistics, a UK governmental body, revealed that total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, a marked acceleration compared to the 0.9% growth recorded in 2022. Hence, the surge in healthcare investments will drive the expansion of the sotrovimab or Xevudy market.
Sotrovimab Or Xevudy Market Segment Outlook: Which Categories Are Expanding The Fastest?
The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Pediatric, Adult, Geriatric
Sotrovimab Or Xevudy Market Key Companies And Competitive Benchmarking
Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.
Access The Complete Sotrovimab Or Xevudy Market Report:
Sotrovimab Or Xevudy Market Geographic Distribution And Regional Opportunities
North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model